BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/12/2023 10:19:09 AM | Browse: 132 | Download: 235
 |
Received |
|
2022-09-12 10:08 |
|
Peer-Review Started |
|
2022-09-12 10:09 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-11-15 08:15 |
|
Revised |
|
2022-11-20 12:52 |
|
Second Decision |
|
2022-12-27 03:19 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-12-27 19:26 |
|
Articles in Press |
|
2022-12-27 19:26 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-12-23 07:03 |
|
Typeset the Manuscript |
|
2022-12-28 09:04 |
|
Publish the Manuscript Online |
|
2023-01-12 10:19 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Minireviews |
| Article Title |
Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Mohammad Sadiq Jeeyavudeen, Rahul Chaudhari, Joseph M Pappachan and Sherouk Fouda |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Joseph M Pappachan, FRCP, MD, Consultant Physician-Scientist, Professor, Senior Editor, Senior Researcher, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Sharoe Green Lane, Preston PR2 9HT, United Kingdom. drpappachan@yahoo.co.in |
| Key Words |
Metabolic-associated fatty liver disease; COVID-19; Metabolic syndrome; Non-alcoholic steatohepatitis; Angiotensin converting enzyme 2 |
| Core Tip |
The severity of coronavirus disease 2019 (COVID-19) symptoms and sequelae positively correlate with high rates of hepatic decompensation and elevated transaminases in patients with chronic liver disease and cirrhosis. Implicated mechanisms linking cirrhosis with severe COVID-19 symptoms include cirrhosis-related immune dysregulation, systemic inflammation, coagulopathy, and metabolic derangements. Metabolic-associated fatty liver disease (MAFLD) is characterized as the hepatic manifestation of the metabolic syndrome and therefore is highly associated with other comorbidities such as obesity, diabetes, and hyperlipidemia. Those comorbidities are also risk factors for severe COVID-19. The hepatic distribution of the angiotensin-converting enzyme 2 receptor, the main viral entry receptor for SARS-CoV-2, may determine the severity of hepatic involvement. In addition, moderate hepatic dysfunction could alter the severity of COVID-19, as well as the safety profile, and the therapeutic efficacy of antiviral drugs metabolized in the liver. Therefore, it is of high clinical priority to enhance our understanding of COVID-19 infection-associated liver injury in MAFLD patients to treat both of these conditions effectively. |
| Publish Date |
2023-01-12 10:19 |
| Citation |
Jeeyavudeen MS, Chaudhari R, Pappachan JM, Fouda S. Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease. World J Gastroenterol 2023; 29(3): 487-502 |
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i3/487.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i3.487 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
